Tumor angiogenesis refers to the development of new blood vessels in tumors and is a vital indicator of cancer metastasis which is the major cause of cancer-related deaths. Study of tumor angiogenesis is critical for the development of potential therapeutic strategies of suppressing cancer metastasis. In the current work, a microfluidic device has been developed and was composed of 2 reservoirs connecting with a Matrigel-filled microchannel. The microchannel was mimicked as a biological barrier and embedded with measurement microelectrodes. New blood vessels were successfully induced to extend along the microchannel. Meanwhile, real-time impedance measurement was conducted to quantitatively monitor the tumor angiogenesis process. The results revealed the extension speed of new blood vessels was proportional to chemical induction level, i.e., VEGF165 concentration. Moreover, tumor angiogenesis was shown to be induced by the VEGF released from cancer cells and significantly correlated to the number of cancer cells. In addition, anti-VEGF suppressor was quantitatively evaluated to study the suppression efficacy of tumor angiogenesis. The current microfluidic device provides a promising tool to study tumor angiogenesis in 3D biological barrier. The impedance technique offers reliable and quantitative evidences for evaluating drug efficacy. Development of tumor angiogenesis analytical platform can potentially lead to develop novel therapeutic strategies of suppressing cancer metastasis.

肿瘤血管生成是指肿瘤中新血管的发育，是癌症转移的重要指标，是癌症相关死亡的主要原因。肿瘤血管生成的研究对于开发抑制癌症转移的潜在治疗策略至关重要。在目前的工作中，已经开发了一种微流体装置，该装置由 2 个与填充基质胶的微通道连接的储液器组成。微通道被模拟为生物屏障并嵌入了测量微电极。成功诱导新血管沿微通道延伸。同时，进行实时阻抗测量以定量监测肿瘤血管生成过程。结果表明，新血管的延伸速度与化学诱导水平成正比，即 VEGF165 浓度。此外，肿瘤血管生成被证明是由癌细胞释放的 VEGF 诱导的，并且与癌细胞的数量显着相关。此外，对抗VEGF抑制剂进行了定量评估，以研究肿瘤血管生成的抑制效果。目前的微流体装置为研究 3D 生物屏障中的肿瘤血管生成提供了一种有前途的工具。阻抗技术为评估药物疗效提供了可靠和定量的证据。肿瘤血管生成分析平台的开发可能会导致开发抑制癌症转移的新治疗策略。定量评估抗VEGF抑制剂以研究肿瘤血管生成的抑制功效。目前的微流体装置为研究 3D 生物屏障中的肿瘤血管生成提供了一种有前途的工具。阻抗技术为评估药物疗效提供了可靠和定量的证据。肿瘤血管生成分析平台的开发可能会导致开发抑制癌症转移的新治疗策略。定量评估抗VEGF抑制剂以研究肿瘤血管生成的抑制功效。目前的微流体装置为研究 3D 生物屏障中的肿瘤血管生成提供了一种有前途的工具。阻抗技术为评估药物疗效提供了可靠和定量的证据。肿瘤血管生成分析平台的开发可能会导致开发抑制癌症转移的新治疗策略。